News
| 9 May 2018 |
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International ConferenceLONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present… |
| 8 May 2018 |
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018Announced positive top-line data from two Phase 2 clinical trials ahead of schedule |
| 4 May 2018 |
Verona Pharma to Present at Bio€quity Europe 2018LONDON, May 04, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Piers Mor… |
| 3 May 2018 |
Result of AGM03 May 2018, London– Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General M… |
| 2 May 2018 |
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018LONDON, May 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report… |
| 11 April 2018 |
Verona Pharma Announces Departure of Chief Medical OfficerLONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today a… |
| 26 March 2018 |
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDPrimary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels |
| 26 March 2018 |
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDPrimary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels |
| 15 March 2018 |
Verona Pharma to Present at Upcoming Healthcare Investor ConferencesLONDON, March 15, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced that Company… |
| 9 March 2018 |
2017 Annual Report and Accounts and Notice of AGMMarch 9, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the A… |
Targeting unmet needs
384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Read more about COPD and CF in the unmet needs section of this website
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2018
